Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/06/2026 ,inter alia, to consider and approve Ratification of Approval ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shukra Pharmaceuticals has called a board meeting on 10 June 2026 to consider ratifying a shareholder resolution originally passed at an EGM on 1 November 2025. The original allotment had received BSE in-principle approval on 9 January 2026 but was not completed within the mandatory 15-day window, prompting BSE to ask for ratification. The company will seek shareholder approval for the ratification via a postal ballot under SEBI ICDR Regulation 170(2). A draft postal ballot notice will also be approved at the meeting.
This is primarily a procedural compliance step to regularise a delayed past allotment. If the underlying allotment involves fresh equity issuance, shareholders may face potential dilution once ratified; otherwise, the impact on the stock is likely limited.